Goldman Sachs analyst Olivier Nicolai upgraded Haleon (HLN) to Buy from Neutral with a 440 GBp price target The firm sees the company’s fundamentals inflecting in fiscal 2026 due to stronger volume, a U.S. recovery and ongoing high-single-digit Oral Health growth. With Haleon’s organic sales growth positioned to accelerate into 2026, the shares are trading at an attractive entry point, the analyst tells investors in a research note.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HLN: